📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-02 20:42
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
15 announcements match the current filters (relevance ≥ 5).
Aarti Pharmalabs Receives ₹59.50 Cr Stamp Duty & Penalty Demand; Plans Legal Challenge
The Office of the Superintendent of Stamps, Gujarat, has levied a total demand of ₹59.50 Cr on Aarti Pharmalabs regarding the adjudication of stamp duty on its 2022 demerger from Aarti Industries. The demand consists of ₹25.0 Cr base stamp duty, ₹25.0 Cr penalty, and an additional penalty of ₹9.50 Cr. The aggregate claim represents ~27.9% of the company's TTM net profit (₹213 Cr) and ~3.0% of its net worth (₹1,982 Cr). The company stated it has strong grounds on merits and will legally challenge the order.
Confidence: HIGH
What changedGujarat stamp authorities issued an adverse demand order for ₹59.50 Cr (duty + penalties) on the 2022 demerger from Aarti Industries.
Why it mattersThe liability is sizable relative to annual profitability (~28% of TTM PAT), posing cash outflow risk if legal relief or stay is not obtained.
Total demand: Rs. 59,50,00,000/-Base stamp duty: Rs. 25 CroresPenalties levied: Rs. 34.50 CroresDemand vs TTM PAT: ~27.9%Demand vs Net Worth: ~3.0%
📅 Short termMay weigh on stock sentiment in the near term as the market assesses potential cash provisioning or pre-deposit requirements.
📈 Long termLimited structural risk to ongoing operations, though resolution in stamp duty litigation typically involves extended legal timelines.
⚠ Risk flags
- Potential cash outflow of up to ₹59.50 Cr if legal challenge fails
- Requirement of statutory pre-deposit to secure a stay on demand
Key Highlights
Total demand of ₹59.50 Cr levied under the Gujarat Stamp Act, 1958
Breakdown includes ₹25.0 Cr stamp duty, ₹25.0 Cr penalty, and ₹9.50 Cr additional penalty
Pertains to the NCLT-sanctioned demerger scheme approved on September 21, 2022
Total exposure amounts to ~27.9% of TTM PAT (₹213 Cr)
Management intends to challenge the order before higher appellate forums
👀 What to Watch
Track the filing of appeals, application for interim stay, and whether any mandatory pre-deposit is required during the appellate process.
9,600 MTPA: Aarti Pharmalabs expands Xanthine capacity; Q1 EBITDA margin hits 24.75%
Aarti Pharmalabs reported Q1 FY27 consolidated revenue of ₹535.8 Cr, showing strong operational performance with EBITDA margins expanding to 24.75% from 22.12% in FY26. The company has successfully commissioned its Xanthine capacity expansion at Tarapur Unit 5, reaching 9,600 MTPA, which is expected to increase its global market share to 20-25%. The CDMO segment continues to scale, with FY26 sales at ₹276 Cr and 37 commercial projects currently active. Additionally, a 6-week debottlenecking at the Unit 4 Steroid block has unlocked 33% additional capacity.
Confidence: HIGH
What changedThe company has transitioned to a higher capacity base in its Xanthine business and completed critical debottlenecking in its Steroid API block, while shifting to JV accounting for Ganesh Polychem.
Why it mattersThe capacity expansion in Xanthines (Caffeine) targets a dominant 20-25% global market share, while the scaling CDMO business and Atali Greenfield site provide a long-term growth runway beyond generic APIs.
Q1 FY27 Consolidated Revenue: ₹535.8 CrQ1 EBITDA Margin: 24.75%Xanthine Capacity: 9,600 MTPAQ1 Revenue vs TTM Revenue: 29.4%Net Debt to Equity: 0.32x
📅 Short termThe stock may react positively to the margin expansion and the successful commissioning of the Xanthine capacity, which provides immediate volume growth potential.
📈 Long termStructural growth is supported by the 'China+1' strategy in Xanthines and the 80-acre Atali land bank, which allows for 8-10x scaling of the initial CDMO capacity.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Elevated raw material prices due to geopolitical tensions
- High dependency on imports (33%+)
- Susceptibility to forex fluctuations
Key Highlights
Xanthine capacity nearly doubled from 5,000 MTPA to 9,600+ MTPA at Tarapur Unit 5
Consolidated EBITDA margin improved to 24.75% in Q1 FY27, up from 22.12% in FY26
CDMO segment revenue reached ₹276 Cr in FY26, supported by 3 R&D centers and 57 active projects
Unit 4 Steroid API block capacity increased by 33% following a successful 6-week debottlenecking shutdown
R&D investment for FY26 stood at ₹65 Cr, representing 7.4% of API and CDMO sales
👀 What to Watch
Monitor the volume ramp-up of the newly commissioned 9,600 MTPA Xanthine capacity and the utilization levels of the Atali Greenfield Phase 1 (450+ kL) for CDMO growth. Watch for the impact of elevated raw material prices on margins in the coming quarters.
Rs 149 Cr Capex for 405 KL Capacity Addition & Strong Q1 PAT Growth of 49% YoY
Aarti Pharmalabs has approved a Rs 149 crore investment to develop a new Intermediate Block with a 405 KL capacity, targeting the CDMO segment. This capex represents approximately 7.5% of the company's net worth and is slated for completion within one year. Alongside this, the company reported robust Q1 FY27 standalone results, with revenue rising 42.4% YoY to Rs 534.6 crore and Net Profit increasing 49.3% YoY to Rs 71.3 crore. The board also approved the transition of Rashesh C. Gogri to Managing Director effective October 1, 2026.
Confidence: HIGH
What changedThe company has initiated a significant capacity expansion for its CDMO business and reported a sharp recovery in quarterly financial performance compared to the previous year.
Why it mattersThe expansion into intermediates and CDMO services is a key part of the company's strategy to move up the value chain and reduce reliance on commoditized APIs, while the strong Q1 results indicate improved operational efficiency.
Proposed Capex: Rs 149 CroresCapacity Addition: 405 KLCapex vs Net Worth: ~7.5%Q1 Standalone Revenue Growth (YoY): 42.4%Q1 Standalone PAT Growth (YoY): 49.3%Completion Timeline: 1 year
📅 Short termThe stock is likely to react positively to the strong earnings growth and the clear roadmap for capacity expansion in high-margin segments.
📈 Long termThe 405 KL addition and the focus on CDMO services provide a structural growth lever for the next 2-3 years, potentially improving the company's return profile and market positioning.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk within the 1-year timeline
- Increased debt levels as financing includes borrowings
- Susceptibility to raw material price spikes
Key Highlights
Approved Rs 149 crore capex for a new Intermediate Block to serve CDMO and intermediate customers.
Proposed capacity addition of 405 KL to be commissioned within a 12-month timeline.
Standalone Q1 FY27 revenue grew 42.4% YoY to Rs 534.59 crore from Rs 375.31 crore.
Standalone Q1 FY27 Net Profit rose 49.3% YoY to Rs 71.31 crore from Rs 47.75 crore.
Management shift: Rashesh C. Gogri to become MD, while Hetal Gogri Gala moves to Executive Director role.
👀 What to Watch
Monitor the execution of the 405 KL capacity addition over the next four quarters and observe if the strong Q1 margin performance is sustained amidst potential raw material price volatility.
₹149 Cr Capex for CDMO Expansion and Management Reshuffle at Aarti Pharmalabs
Aarti Pharmalabs reported a strong Q1 FY27 with standalone revenue of ₹534.59 cr, up 42.4% YoY from ₹375.31 cr. The board approved a fresh ₹149 cr investment to add 405 KL capacity for an Intermediate Block targeting CDMO customers, representing ~8.2% of TTM revenue. Leadership roles are shifting effective October 1, 2026, with Rashesh C. Gogri moving from Non-Executive to Managing Director. Standalone PAT for the quarter grew 49.3% YoY to ₹71.31 cr, reflecting improved operational performance.
Confidence: HIGH
What changedThe company has committed to a new capacity expansion for intermediates and reshuffled its top management roles while delivering strong double-digit earnings growth.
Why it mattersThe ₹149 cr expansion specifically targets the high-margin CDMO segment, which is a key pillar for the company's long-term valuation re-rating beyond bulk drugs.
Q1 FY27 Standalone Revenue: ₹534.59 crProposed Capex: ₹149 crCapex vs TTM Revenue: ~8.2%Proposed Capacity Addition: 405 KLQ1 FY27 Standalone PAT: ₹71.31 cr
📅 Short termThe stock is likely to react positively to the 42% YoY revenue growth and the announcement of growth-oriented capex.
📈 Long termThe focus on CDMO capacity and the 1-year execution timeline for the new block suggests a clear path toward higher-margin revenue streams over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk for the 1-year capex timeline
- Susceptibility to raw material price spikes affecting EBITDA margins
Key Highlights
Approved ₹149 cr investment for a new 405 KL Intermediate Block to be completed within 1 year
Standalone Revenue for Q1 FY27 increased 42.4% YoY to ₹534.59 cr
Standalone PAT grew 49.3% YoY to ₹71.31 cr compared to ₹47.75 cr in the previous year
Rashesh C. Gogri appointed as Managing Director effective October 1, 2026
Hetal Gogri Gala to transition from Managing Director to Executive Director from October 1, 2026
👀 What to Watch
Monitor the execution timeline of the ₹149 cr intermediate block and the ramp-up of the Atali Greenfield site which is central to the company's CDMO growth strategy.
Rs 149 Cr Capex and 49% YoY Profit Growth in Q1 FY27
Aarti Pharmalabs reported a strong Q1 FY27 with standalone revenue growing 42.4% YoY to Rs 534.59 Cr. Net profit for the quarter rose 49.3% YoY to Rs 71.31 Cr, driven by improved operational performance. The board approved a new Rs 149 Cr capex for a 405 KL Intermediate Block to serve CDMO customers, to be completed within one year. Additionally, a leadership transition was announced with Rashesh C. Gogri set to become Managing Director effective October 1, 2026.
Confidence: HIGH
What changedThe company reported a significant YoY earnings jump and committed to a fresh Rs 149 Cr capacity expansion for its intermediate and CDMO business.
Why it mattersThe expansion into intermediates and CDMO services is a higher-margin pivot from bulk drugs, and the strong Q1 results suggest the company is successfully managing raw material costs and volume growth.
Revenue (Q1 FY27): Rs 534.59 CrNet Profit (Q1 FY27): Rs 71.31 CrProposed Capex: Rs 149 CrCapex vs TTM Revenue: ~8.2%Proposed Capacity Addition: 405 KLEPS (Q1 FY27): Rs 7.87
📅 Short termThe stock is likely to react positively to the strong YoY profit growth and the announcement of new growth-oriented capex.
📈 Long termThe structural shift toward CDMO and the doubling of Xanthine capacity by Q4 FY26 provide a clear growth runway over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High dependency on imports (33%+)
- Susceptibility to raw material price spikes
- Forex volatility as noted in the audit restatement
Key Highlights
Standalone Revenue from Operations increased 42.4% YoY to Rs 534.59 Cr from Rs 375.31 Cr.
Standalone Net Profit grew 49.3% YoY to Rs 71.31 Cr compared to Rs 47.75 Cr in the previous year.
Approved Rs 149 Cr investment for a new 405 KL Intermediate Block capacity expansion.
Management transition effective Oct 1, 2026, with Rashesh C. Gogri moving from Non-Executive to Managing Director.
Capex of Rs 149 Cr represents approximately 8.2% of TTM Revenue (Rs 1820 Cr).
👀 What to Watch
Monitor the execution timeline of the new 405 KL intermediate block and the ramp-up of the Atali Greenfield site which is central to the CDMO growth strategy.
3,600 TPA Expansion: Aarti Pharmalabs Boosts Xanthine Capacity to 9,600 TPA at Tarapur
Aarti Pharmalabs has inaugurated a new 3,600 TPA manufacturing block for Xanthine derivatives at its Tarapur Unit 5 facility. This expansion increases the company's total capacity for these products to 9,600 TPA, representing a 60% increase from its previous base. The company now ranks among the top three global manufacturers of Xanthine derivatives, which are critical for the beverage and pharmaceutical industries. Trial production has commenced, with a full ramp-up expected over the next few quarters.
Confidence: HIGH
What changedThe company has transitioned from the construction phase to the production phase for its Tarapur brownfield expansion, adding significant new capacity for its core Xanthine product line.
Why it mattersThis expansion directly supports the company's goal of capturing a larger wallet share of the global beverage market and leverages its existing infrastructure to drive volume-led growth.
New Capacity Added: 3,600 TPATotal Post-Expansion Capacity: 9,600 TPACapacity Increase Percentage: 60%TTM Revenue: Rs 1,820 CrMarket Cap: Rs 6,238 Cr
📅 Short termThe inauguration is a positive milestone that validates execution timelines; however, financial benefits will accrue gradually as production ramps up over the next 2-3 quarters.
📈 Long termStrengthens the company's competitive position in the global nutraceutical and API supply chain, supporting its long-term growth target of 8-12%.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Ramp-up delays
- Raw material price volatility
- Global competition in the Xanthine market
Key Highlights
Inaugurated a new 3,600 TPA manufacturing block at Tarapur Unit 5, Maharashtra
Total Xanthine derivative capacity increased to 9,600 TPA, a 60% capacity jump
Company now positioned among the top 3 Xanthine derivatives manufacturers globally
Trial production has already been initiated as of June 30, 2026
Ramp-up for optimum utilization is scheduled over the next few quarters
👀 What to Watch
Monitor the pace of capacity utilization ramp-up in the upcoming quarterly results and its impact on the current 21.2% operating margins. Watch for increased revenue contribution from the beverage segment as this facility reaches full scale.
Aarti Pharmalabs Q4 FY26: Revenue Up 9%, CDMO Segment Targets 40-50% Growth in FY27
Aarti Pharmalabs reported a 9% YoY revenue growth in Q4 FY26 to ₹580 crore, although full-year PAT declined to ₹176 crore, impacted by a ₹33 crore net foreign exchange loss. The CDMO segment remains a standout performer, growing 32% in FY26 and projected to grow 40-50% in FY27 as the Atali facility becomes fully operational. The company has maintained a strong growth guidance of 15-18% for both revenue and EBITDA over the next 3-4 years, supported by a ₹400 crore annual capex plan.
Key Highlights
FY26 Revenue stood at ₹1,798 crore with EBITDA at ₹406 crore; Board declared a total dividend of ₹3.50 per share.
CDMO segment reached record quarterly revenue of ₹155 crore with 54 active projects, including 35 in the commercial stage.
Xanthine derivative capacity is expanding from 6,000 MTPA to 9,000 MTPA, with incremental production starting Q1 FY27.
Atali Phase 1 (440 kL capacity) is expected to be completely operational by the end of Q1 FY27 after clearing customer audits.
Company is investing in new R&D technologies including peptides and oligonucleotides for long-term future potential.
👀 What to Watch
Investors should focus on the execution of the CDMO segment's high-growth guidance and the successful ramp-up of the Atali facility to offset margin pressures in the API business. The stock remains a growth play with a clear 15-18% CAGR outlook, though short-term profitability has been impacted by forex and competitive headwinds.
Aarti Pharmalabs Q4 FY26: Revenue up 9.5% YoY to ₹580 Cr; CDMO Segment hits record high
Aarti Pharmalabs reported a 9.5% YoY increase in Q4 FY26 standalone revenue to ₹5,797 Mn, though EBITDA margins contracted to 23.1% from 31.2% in the previous year. The CDMO segment achieved its highest-ever quarterly revenue of ₹155 Cr, driven by large order deliveries. While annual PAT for FY26 declined by 31.5% to ₹1,762 Mn due to higher finance costs and forex impacts, the company is targeting a 15-18% CAGR over the next 3-4 years. Significant capacity expansions in Xanthine derivatives and the Atali greenfield project are expected to be fully operational by June 2026.
Key Highlights
Q4 FY26 Standalone Revenue grew 9.5% YoY to ₹5,797 Mn, with CDMO revenue reaching a record ₹155 Cr.
EBITDA margins for Q4 FY26 stood at 23.1%, down from 31.2% YoY, impacted by input costs and logistics.
Xanthine capacity expansion to 9,000 MTPA and Atali Phase 1 (450 KL) to be fully operational by June 2026.
FY26 Capex reached ~₹400 Cr, with a similar investment planned for FY27 including new R&D in TIDES.
Management targets a 15-18% Revenue and EBITDA CAGR over the next 3-4 years.
👀 What to Watch
Investors should monitor the margin recovery as new capacities at Atali and Tarapur become operational in Q1 FY27. The strong growth in the high-margin CDMO segment is a positive long-term driver despite current bottom-line pressure.
Aarti Pharmalabs Unit-IV Tarapur US-FDA Inspection Concludes with 1 Procedural Observation
Aarti Pharmalabs Limited has announced the completion of a US-FDA inspection at its Unit-IV facility in Tarapur, Maharashtra, on March 27, 2026. The inspection resulted in the issuance of a Form 483 with only one observation, which the company has characterized as procedural in nature. The company is committed to submitting corrective and preventive actions (CAPA) within the stipulated timeframe. This outcome is generally viewed as positive for a pharmaceutical company, as a single procedural observation suggests high compliance standards and minimal risk to existing operations.
Key Highlights
US-FDA inspection at Unit-IV, Tarapur concluded on March 27, 2026
Form 483 issued with only 01 (one) observation
Observation is classified as procedural in nature rather than a data integrity or safety issue
Company to submit corrective and preventive actions (CAPA) within the required period
👀 What to Watch
Investors should view this as a positive regulatory development as it indicates a low level of non-compliance. Monitor for the receipt of the Establishment Inspection Report (EIR) which will signify the formal closure of the inspection.
Aarti Pharmalabs Q3 FY26: Revenue at ₹425 Cr, PAT at ₹44 Cr; Declares ₹1.5 Interim Dividend
Aarti Pharmalabs reported a decline in Q3 FY26 revenue to ₹425 crores from ₹471 crores YoY, primarily due to pricing pressure in the API segment and operational delays at the new Atali plant. Profit After Tax (PAT) fell significantly to ₹44 crores compared to ₹74 crores in the same period last year. Management noted that ₹49 crores of revenue was deferred as goods in transit, which impacted the quarter's PBT by ₹19 crores. Consequently, the company has revised its FY26 outlook, expecting EBITDA to be largely in line with the previous year with only marginal growth.
Key Highlights
Revenue decreased 9.8% YoY to ₹425 crores, while PAT dropped to ₹44 crores from ₹74 crores.
Deferred revenue of ₹49 crores due to goods in transit impacted Q3 PBT by ₹19 crores, expected to be realized in Q4.
CDMO segment remains a growth driver with 59 active projects, 40 of which are in the commercial stage.
Atali plant Phase 1 (₹300 crore capitalized) faced stabilization hiccups, delaying some CDMO validation quantities to Q4.
Board declared an interim dividend of ₹1.5 per share despite the earnings contraction.
👀 What to Watch
Investors should monitor the stabilization of the Atali plant and the ramp-up of Xanthine expansion in FY27, as FY26 growth is expected to be muted. The stock may face near-term pressure until API margins stabilize and new capacities begin contributing to the bottom line.
Aarti Pharmalabs Q3 Standalone PAT Falls 40% YoY to ₹43.8 Cr; EBITDA Margin Stable at 24.2%
Aarti Pharmalabs reported a 9.7% YoY decline in standalone revenue to ₹425.3 crore for Q3-FY26, while PAT dropped 40.4% YoY to ₹43.8 crore, impacted by higher depreciation and finance costs. Despite the YoY decline, the company showed a strong sequential recovery with EBITDA rising 39% QoQ and margins remaining resilient at 24.22%. The CDMO segment is a key growth driver with 30-40% growth projected for FY26, although ₹49 crore in revenue was deferred this quarter due to goods in transit. Major capacity expansions in Xanthine (to 9,000 MTPA) and the Atali greenfield site are nearing completion, positioning the company for future scale.
Key Highlights
Standalone revenue for Q3-FY26 stood at ₹425.3 crore, down 9.7% YoY but up 1.9% QoQ.
EBITDA margins remained stable at 24.22% vs 24.42% YoY, despite pricing pressures in the API segment.
Xanthine capacity expansion from 5,000 MTPA to 9,000 MTPA is on track for completion by March 2026.
CDMO segment currently has 59 active projects with 21 customers, expecting 30-40% revenue growth in FY26.
Net Debt/Equity ratio remains low at 0.26x, supporting ongoing total capex plans of approximately ₹550 crore.
👀 What to Watch
Investors should monitor the successful ramp-up of the Atali greenfield site and the commissioning of the Xanthine expansion in Q4-FY26. While YoY earnings are soft, the sequential recovery and strong CDMO pipeline suggest long-term growth potential.
Aarti Pharmalabs Declares ₹1.5 Interim Dividend; Record Date Set for Feb 16, 2026
Aarti Pharmalabs Limited has announced an interim dividend of ₹1.5 per equity share for the financial year 2024-25, representing a 30% payout on the face value of ₹5. The decision was finalized during the Board of Directors meeting held on February 09, 2026. The company has designated February 16, 2026, as the record date to identify shareholders eligible for the payout. This move reflects the company's commitment to returning value to its shareholders through consistent payouts.
Key Highlights
Interim dividend of ₹1.5 per equity share declared for FY 2024-25
Dividend payout is 30% of the face value of ₹5 per share
Record date for dividend eligibility is fixed as February 16, 2026
Board meeting for the declaration took place on February 09, 2026
👀 What to Watch
Investors interested in the dividend must ensure they hold the shares before the ex-dividend date, typically one working day prior to the February 16 record date. Long-term investors should view this as a positive sign of cash flow management.
Aarti Pharmalabs Q3 Net Profit at ₹47.96 Cr; Declares ₹1.50 Interim Dividend
Aarti Pharmalabs reported a consolidated net profit of ₹47.96 crore for the quarter ended December 31, 2025, a decline from ₹73.99 crore in the corresponding quarter of the previous year. Consolidated revenue from operations stood at ₹274.11 crore, which was impacted by ₹49.35 crore of revenue being deferred to Q4 due to goods being in transit. The company has declared an interim dividend of ₹1.50 per share (30% of face value). An exceptional item of ₹2.79 crore was recorded due to provisions for new labour codes.
Key Highlights
Consolidated Net Profit for Q3 FY26 stood at ₹47.96 crore, down 35% YoY from ₹73.99 crore.
Revenue from operations was ₹274.11 crore, with an additional ₹49.35 crore in-transit revenue deferred to Q4.
Declared an interim dividend of ₹1.50 per equity share with a record date of February 16, 2026.
Exceptional charge of ₹279.49 lakhs recognized for incremental provision under new labour codes.
Consolidated EPS for the quarter fell to ₹5.29 from ₹8.16 in the year-ago period.
👀 What to Watch
Investors should monitor the Q4 results closely to see if the deferred revenue of ₹49.35 crore translates into a strong recovery in profitability. While the dividend provides some support, the year-on-year decline in earnings suggests a cautious approach until margins stabilize.
Aarti Pharmalabs Declares ₹1.5 Interim Dividend; Q3 Net Profit Rises to ₹47.96 Crore
Aarti Pharmalabs has declared an interim dividend of ₹1.5 per equity share (30% of face value) for FY 2025-26, with the record date set for February 16, 2026. For the quarter ended December 31, 2025, the company reported a consolidated net profit of ₹47.96 crore, a significant increase from ₹27.92 crore in the previous quarter. Although consolidated revenue dipped sequentially to ₹273.37 crore, the company noted that ₹49.35 crore in revenue was deferred to Q4 due to goods being in-transit. An exceptional provision of ₹2.79 crore was also made for new labour code compliance.
Key Highlights
Declared interim dividend of ₹1.5 per equity share (30% on face value of ₹5)
Consolidated Net Profit grew to ₹47.96 crore in Q3 FY26 from ₹27.92 crore in Q2 FY26
Revenue of ₹49.35 crore deferred to Q4 FY26 due to goods in-transit at quarter-end
Exceptional item of ₹2.79 crore provisioned for impact of new labour codes
Record date for dividend eligibility fixed as Monday, February 16, 2026
👀 What to Watch
Investors should benefit from the dividend payout and the strong bottom-line growth. The deferred revenue from in-transit goods suggests a potentially robust Q4, supporting a positive outlook for the stock.
Aarti Pharmalabs Appoints Dr. Rakeshwar Bandichhor as Chief Scientific Officer - R&D
Aarti Pharmalabs has appointed Dr. Rakeshwar Bandichhor as Chief Scientific Officer for R&D and Senior Management Personnel, effective January 1, 2026. Dr. Bandichhor brings over 25 years of extensive experience in API-R&D and Process Chemistry to the company. He joins from Dr. Reddy's Laboratories and holds a Ph.D. with postdoctoral experience from prestigious institutions in Germany and the USA. This appointment is expected to strengthen the company's technical leadership and research capabilities in the pharmaceutical space.
Key Highlights
Dr. Rakeshwar Bandichhor appointed as Chief Scientific Officer - R&D effective January 1, 2026
Brings 25 years of rich experience in API-R&D and Process Chemistry
Previously associated with industry major Dr. Reddy's Laboratories in Hyderabad
Holds a Ph.D. and completed three postdoctoral trainings at universities in Germany and the USA
👀 What to Watch
Investors should view this as a positive step towards enhancing the company's R&D and API development capabilities. Monitor for future announcements regarding new product pipelines or process improvements under the new leadership.
